呼吸器感染症に対するAC-1370の臨床的検討

中西 通泰; 桜井 信男; 村山 尚子; 前川 暢夫; 稲葉 宣雄; 小田 芳郎; 内平 文章; 池田 宣昭; 岩田 猛邦; 角田 沖介; 坂本 広子; 石原 享介

doi:10.11250/chemotherapy1953.32.Supplement9_353

CLINICAL STUDIES ON AC-1370 IN THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

MICHIYASU NAKANISHI, NOBUO SAKURAI, TAKAKO MURAYAMA, NOBUO MAEKAWA, NOBUO INABA, YOSHIRO ODA, FUMIAKI UCHIHIRA, NOBUAKI IKEDA, TAKEKUNI IWATA, OKISUKE TSUNODA, HIROKO SAKAMOTO, RYOSUKE ISHIHARA

Author information

MICHIYASU NAKANISHI
Chest Disease Research Institute, Kyoto University
NOBUO SAKURAI
Chest Disease Research Institute, Kyoto University
TAKAKO MURAYAMA
Chest Disease Research Institute, Kyoto University
NOBUO MAEKAWA
Chest Disease Research Institute, Kyoto University
NOBUO INABA
Osaka Red Cross Hospital
YOSHIRO ODA
Osaka Red Cross Hospital
FUMIAKI UCHIHIRA
Osaka Red Cross Hospital
NOBUAKI IKEDA
Kokuritsuryoyojo Minamikyoto Hospital
TAKEKUNI IWATA
Tenri Hospital
OKISUKE TSUNODA
Kobe Tamatsu Hospital
HIROKO SAKAMOTO
Kobe Tamatsu Hospital
RYOSUKE ISHIHARA
Kobe Central City Hospital

JOURNAL FREE ACCESS

1984 Volume 32 Issue Supplement9 Pages 353-358

DOI https://doi.org/10.11250/chemotherapy1953.32.Supplement9_353

Details

Abstract

AC-1370, a new cephalosporin antibiotic, was applied for the treatment of 14 patients with respiratory tract infections.
The drug was administered intravenously, 2-4 g/day, divided into two doses, for the period of 3 to 22 days.
The results were as follows, excellent in three cases, good in four cases, slightly good in three cases, ineffective in one case.
Remaining three cases were excluded due to unsuitability for the trial. Effectiveness rate was 63.6%. Side effect was found in one case (rash), and abnormal laboratory data were found in three cases.

Corresponding author

Register with J-STAGE for free!